Zhang Linqi (L), a professor at School of Medicine of Tsinghua University, presents two medicine samples during a press conference at Tsinghua University, Beijing, Dec. 9, 2021. (Photo: China News Service/Jia Tianyong)
Two medicines for COVID-19 neutralizing antibody combination therapy manufactured by Brii Biosciences Limited, amubarvimab and romlusevimab (previously BRII-196 and BRII-198), were approved by the National Medical Products Administration (NMPA) on Wednesday.
Jointly developed by a research team led by Professor Zhang Linqi of Tsinghua University, the treatment is China's first COVID-19 neutralizing antibody combination therapy with independent intellectual property rights.
Photo taken on Dec. 9, 2021, shows medicine samples of amubarvimab and romlusevimab (previously BRII-196 and BRII-198), in Beijing. (Photo: China News Service/Jia Tianyong)
Professor Zhang Linqi introduces the characteristics and development process of drugs during a press conference at Tsinghua University, Beijing, Dec. 9, 2021. (Photo: China News Service/Jia Tianyong)
Professor Zhang Linqi introduces the characteristics of drugs during a press conference at Tsinghua University, Beijing, Dec. 9, 2021. (Photo: China News Service/Jia Tianyong)
京公网安备 11010202009201号